Kidney Cancer

  • Robert AbouassalyEmail author
  • Steven C. Campbell


The increased use of abdominal imaging has contributed to a rise in the incidence of kidney tumors. Notably the greatest increase has been in small renal masses among older adults. This has led to a treatment dilemma given the unclear impact of these small tumors on life expectancy, particularly in patients with advanced age or multiple comorbidities. This has contributed to the development of minimally invasive treatment approaches as well as the use of active surveillance for this disease. This chapter provides a concise review of the epidemiology, etiology, diagnosis, and treatment of kidney cancer, with particular focus on elderly patients.


Chronic Kidney Disease Renal Cell Carcinoma Active Surveillance Partial Nephrectomy Renal Mass 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    American Cancer Society. Cancer Facts and Figures 2011. American Cancer Society (2011). Accessed 17 Aug 2011.Google Scholar
  2. 2.
    Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193–205.PubMedCrossRefGoogle Scholar
  3. 3.
    Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006;176(6 Pt 1):2353–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166(5):1611–23.PubMedCrossRefGoogle Scholar
  5. 5.
    Nguyen CT, Campbell SC. Staging of renal cell carcinoma: past, present, and future. Clin Genitourin Cancer. 2006;5(3):190–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Chow WH, Devesa SS, Warren JL, Fraumeni Jr JF. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281(17):1628–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Katz DL, Zheng T, Holford TR, Flannery J. Time trends in the incidence of renal carcinoma: analysis of Connecticut tumor registry data, 1935–1989. Int J Cancer. 1994;58(1):57–63.PubMedCrossRefGoogle Scholar
  8. 8.
    Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78.PubMedCrossRefGoogle Scholar
  9. 9.
    Clague J, Lin J, Cassidy A, et al. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev. 2009;18(3):801–7.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Romanenko A, Morell-Quadreny L, Nepomnyaschy V, Vozianov A, Llombart-Bosch A. Pathology and proliferative activity of renal-cell carcinomas (RCCS) and renal oncocytomas in patients with different radiation exposure after the Chernobyl accident in Ukraine. Int J Cancer. 2000;87(6):880–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Dhote R, Thiounn N, Debre B, Vidal-Trecan G. Risk factors for adult renal cell carcinoma. Urol Clin North Am. 2004;31(2):237–47.PubMedCrossRefGoogle Scholar
  12. 12.
    Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Abouassaly R. Predictors of partial nephrectomy utilization and inequities of care in the treatment of renal cell carcinoma in Canada. [M.Sc. Thesis]. Toronto, Canada: University of Toronto; 2010.Google Scholar
  14. 14.
    Jun C, Zhishun X, Xianzhou J, Qiang F, Jin W. Association between age and clinical characteristics of renal cell carcinoma in adult patients. Int J Urol. 2006;13(5):515–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51(2):203–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982–1997). Urology. 2000;56(1):58–62.PubMedCrossRefGoogle Scholar
  17. 17.
    Gold PJ, Fefer A, Thompson JA. Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol. 1996;14(4):216–22.PubMedGoogle Scholar
  18. 18.
    Bach AM, Zhang J. Contemporary radiologic imaging of renal cortical tumors. Urol Clin North Am. 2008;35(4):593–604.PubMedCrossRefGoogle Scholar
  19. 19.
    Rothman J, Egleston B, Wong YN, Iffrig K, Lebovitch S, Uzzo RG. Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol. 2009;181(1):29–33. discussion 33–4.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Skolarus TA, Serrano MF, Berger DA, et al. The distribution of histological subtypes of renal tumors by decade of life using the 2004 WHO classification. J Urol. 2008;179(2):439–43.PubMedCrossRefGoogle Scholar
  21. 21.
    Lane BR, Babineau D, Kattan MW, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol. 2007;178(2):429–34.PubMedCrossRefGoogle Scholar
  22. 22.
    Eggener SE, Rubenstein JN, Smith ND, et al. Renal tumors in young adults. J Urol. 2004;171(1):106–10.PubMedCrossRefGoogle Scholar
  23. 23.
    Snyder ME, Bach A, Kattan MW, Raj GV, Reuter VE, Russo P. Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: influence of sex. J Urol. 2006;176(6 Pt 1):2391–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Novick AC, Campbell SC, et al. Guideline for management of the clinical stage 1 renal mass. Linthicum, MD: American Urological Association Education and Research; 2009.Google Scholar
  25. 25.
    Seaman E, Goluboff ET, Ross S, Sawczuk IS. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urology. 1996;48(5):692–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Herts BR, Baker ME. The current role of percutaneous biopsy in the evaluation of renal masses. Semin Urol Oncol. 1995;13(4):254–61.PubMedGoogle Scholar
  27. 27.
    Schmidbauer J, Remzi M, Memarsadeghi M, et al. Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses. Eur Urol. 2008;53(5):1003–11.PubMedCrossRefGoogle Scholar
  28. 28.
    Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC. Renal mass biopsy–a renaissance? J Urol. 2008;179(1):20–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):987–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Teloken PE, Thompson RH, Tickoo SK, et al. Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol. 2009;182(5):2132–6.PubMedCrossRefGoogle Scholar
  31. 31.
    de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25(3):275–84.PubMedCrossRefGoogle Scholar
  32. 32.
    Gillett MD, Cheville JC, Karnes RJ, et al. Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol. 2005;173(6):1893–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Komai Y, Fujii Y, Iimura Y, et al. Young age as favorable prognostic factor for cancer-specific survival in localized renal cell carcinoma. Urology. 2011;77(4):842–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Verhoest G, Veillard D, Guille F, et al. Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol. 2007;51(5):1298–304.PubMedCrossRefGoogle Scholar
  35. 35.
    Jeong IG, Yoo CH, Song K, et al. Age at diagnosis is an independent predictor of small renal cell carcinoma recurrence-free survival. J Urol. 2009;182(2):445–50.PubMedCrossRefGoogle Scholar
  36. 36.
    Nguyen CT, Lane BR, Kaouk JH, et al. Surgical salvage of renal cell carcinoma recurrence after thermal ablative therapy. J Urol. 2008;180(1):104–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Ficarra V, Schips L, Guille F, et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer. 2005;104(5):968–74.PubMedCrossRefGoogle Scholar
  38. 38.
    Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Independent validation of the 2002 American Joint Committee on Cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol. 2005;173(6):1889–92.PubMedCrossRefGoogle Scholar
  39. 39.
    Salama ME, Guru K, Stricker H, et al. pT1 substaging in renal cell carcinoma: validation of the 2002 TNM staging modification of malignant renal epithelial tumors. J Urol. 2005;173(5):1492–5.PubMedCrossRefGoogle Scholar
  40. 40.
    Sanchez-Ortiz RF, Rosser CJ, Madsen LT, Swanson DA, Wood CG. Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J Urol. 2004;171(6 Pt 1):2160–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal M, Coulange C. Prognostic value of nuclear grade of renal cell carcinoma. Cancer. 1995;76(12):2543–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89(3):604–14.PubMedCrossRefGoogle Scholar
  43. 43.
    Crispen PL, Boorjian SA, Lohse CM, et al. Outcomes following partial nephrectomy by tumor size. J Urol. 2008;180(5):1912–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Hafez KS, Fergany AF, Novick AC. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol. 1999;162(6):1930–3.PubMedCrossRefGoogle Scholar
  45. 45.
    Thompson RH, Kurta JM, Kaag M, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol. 2009;181(5):2033–6.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Lughezzani G, Jeldres C, Isbarn H, et al. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol. 2009;182(4):1287–93.PubMedCrossRefGoogle Scholar
  47. 47.
    Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol. 2009;181(3):1020–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol. 2002;7(4):135–40.PubMedCrossRefGoogle Scholar
  49. 49.
    Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. 1969;101(3):297–301.PubMedGoogle Scholar
  50. 50.
    Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006;7(9):735–40.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Berger A, Brandina R, Atalla MA, et al. Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more. J Urol. 2009;182(5):2172–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Hollingsworth JM, Miller DC, Dunn RL, Montgomery JS, Wolf Jr JS. Cost trends for oncological renal surgery: support for a laparoscopic standard of care. J Urol. 2006;176(3):1097–101.PubMedCrossRefGoogle Scholar
  53. 53.
    Berdjis N, Hakenberg OW, Novotny V, Froehner M, Wirth MP. Treating renal cell cancer in the elderly. BJU Int. 2006;97(4):703–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Staehler M, Haseke N, Stadler T, et al. Renal surgery in the elderly: morbidity in patients aged >75 years in a contemporary series. BJU Int. 2008;102(6):684–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Roos FC, Hampel C, Thuroff JW. Renal cancer surgery in the elderly. Curr Opin Urol. 2009;19(5):459–64.PubMedCrossRefGoogle Scholar
  56. 56.
    Harano M, Eto M, Yokomizo A, Tatsugami K, Hamaguchi M, Naito S. The efficacy of laparoscopic radical nephrectomy for renal cell cancer in the elderly: an oncological outcome analysis. Int J Urol. 2008;15(7):577–81.PubMedCrossRefGoogle Scholar
  57. 57.
    Hsu TH, Gill IS, Fazeli-Matin S, et al. Radical nephrectomy and nephroureterectomy in the octogenarian and nonagenarian: comparison of laparoscopic and open approaches. Urology. 1999;53(6):1121–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Lai FC, Kau EL, Ng CS, Fuchs GJ. Laparoscopic nephrectomy outcomes of elderly patients in the 21st century. J Endourol. 2007;21(11):1309–13.PubMedCrossRefGoogle Scholar
  59. 59.
    Lowrance WT, Yee DS, Savage C, et al. Complications after radical and partial nephrectomy as a function of age. J Urol. 2010;183(5):1725–30.PubMedCrossRefGoogle Scholar
  60. 60.
    Abouassaly R, Alibhai SM, Tomlinson GA, Urbach DR, Finelli A. The effect of age on the morbidity of kidney surgery. J Urol. 2011;186(3):811–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.PubMedCrossRefGoogle Scholar
  62. 62.
    Ford I, Bezlyak V, Stott DJ, et al. Reduced glomerular filtration rate and its association with clinical outcomes in older patients at risk of vascular events: secondary analysis. PLoS Med. 2009;6(1):76–82.CrossRefGoogle Scholar
  63. 63.
    Rifkin DE, Shlipak MG, Katz RDP, et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med. 2008;168(20):2212–8.PubMedCentralPubMedCrossRefGoogle Scholar
  64. 64.
    Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145(4):237–46.PubMedCrossRefGoogle Scholar
  65. 65.
    Novick AC, Derweesh I. Open partial nephrectomy for renal tumours: current status. BJU Int. 2005;95 Suppl 2:35–40.PubMedCrossRefGoogle Scholar
  66. 66.
    Herr HW. Partial nephrectomy for unilateral renal carcinoma and a normal contralateral kidney: 10-year followup. J Urol. 1999;161(1):33–4.PubMedCrossRefGoogle Scholar
  67. 67.
    Fergany AF, Hafez KS, Novick AC. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol. 2000;163(2):442–5.PubMedCrossRefGoogle Scholar
  68. 68.
    Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Marechal JM, Klotz L, Skinner E, Keane T, Claessens I, Sylvester R, European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Southwest Oncology Group (SWOG), Eastern Cooperative Oncology Group (ECOG). A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2007;51(6):1606–15.PubMedCrossRefGoogle Scholar
  69. 69.
    Stephenson AJ, Hakimi AA, Snyder ME, Russo P. Complications of radical and partial nephrectomy in a large contemporary cohort. J Urol. 2004;171(1):130–4.PubMedCrossRefGoogle Scholar
  70. 70.
    Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000;75(12):1236–42.PubMedCrossRefGoogle Scholar
  71. 71.
    Campbell SC, Novick AC, Streem SB, Klein EA. Management of renal cell carcinoma with coexistent renal artery disease. J Urol. 1993;150(3):808–13.PubMedGoogle Scholar
  72. 72.
    Thompson RH, Leibovich BC, Lohse CM, Zincke H, Blute ML. Complications of contemporary open nephron sparing surgery: a single institution experience. J Urol. 2005;174(3):855–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182(4):1271–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59(4):543–52.PubMedCrossRefGoogle Scholar
  75. 75.
    Stein RJ, Kaouk JH. Renal cryotherapy: a detailed review including a 5-year follow-up. BJU Int. 2007;99(5 Pt B):1265–70.PubMedCrossRefGoogle Scholar
  76. 76.
    Weight CJ, Kaouk JH, Hegarty NJ, et al. Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J Urol. 2008;179(4):1277–81.PubMedCrossRefGoogle Scholar
  77. 77.
    Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma–a meta-analysis and review. J Urol. 2008;179(4):1227–33.PubMedCrossRefGoogle Scholar
  78. 78.
    Mindrup SR, Pierre JS, Dahmoush L, Konety BR. The prevalence of renal cell carcinoma diagnosed at autopsy. BJU Int. 2005;95(1):31–3.PubMedCrossRefGoogle Scholar
  79. 79.
    Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J Urol. 2008;180(2):505–8.PubMedCrossRefGoogle Scholar
  80. 80.
    Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175(2):425–31.PubMedCrossRefGoogle Scholar
  81. 81.
    Lane BR, Abouassaly R, Gao T, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer. 2010;116(13):3119–26.PubMedCrossRefGoogle Scholar
  82. 82.
    Abouassaly R, Yang S, Finelli A, Kulkarni GS, Alibhai SM. What is the best treatment strategy for incidentally detected small renal masses? A decision analysis. BJU Int. 2011;108(8 Pt 2):E223–31.PubMedCrossRefGoogle Scholar
  83. 83.
    Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 1997;80(7):1198–220.PubMedCrossRefGoogle Scholar
  84. 84.
    Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.PubMedCrossRefGoogle Scholar
  86. 86.
    Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071–6.PubMedCrossRefGoogle Scholar
  87. 87.
    Kader AK, Tamboli P, Luongo T, et al. Cytoreductive nephrectomy in the elderly patient: the M.D. Anderson Cancer Center experience. J Urol. 2007;177(3):855–60.PubMedCrossRefGoogle Scholar
  88. 88.
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.PubMedCrossRefGoogle Scholar
  89. 89.
    Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.PubMedCrossRefGoogle Scholar
  90. 90.
    Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90.PubMedCentralPubMedCrossRefGoogle Scholar
  91. 91.
    Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008;100(20):1454–63.PubMedCentralPubMedCrossRefGoogle Scholar
  92. 92.
    Porta C, Calvo E, Climent MA, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 trial. Eur Urol. 2012;61(4):826–33.PubMedCrossRefGoogle Scholar
  93. 93.
    Hutson TE, Bukowski RM, Rini BI, et al. A pooled analysis of the efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. J Clin Oncol. 2011;29:4604. suppl; abstrt.CrossRefGoogle Scholar
  94. 94.
    Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649–57.PubMedGoogle Scholar
  95. 95.
    Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9.PubMedCrossRefGoogle Scholar
  96. 96.
    Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006;24(19):3101–6.PubMedCrossRefGoogle Scholar
  97. 97.
    Muramaki M, Miyake H, Sakai I, et al. Age at diagnosis as a powerful predictor for disease recurrence after radical nephrectomy in Japanese patients with pT1 renal cell carcinoma. Int J Urol. 2011;18(2):121–5.PubMedCrossRefGoogle Scholar
  98. 98.
    Denzinger S, Otto W, Burger M, et al. Sporadic renal cell carcinoma in young and elderly patients: are there different clinicopathological features and disease specific survival rates? World J Surg Oncol. 2007;5:16.PubMedCentralPubMedCrossRefGoogle Scholar
  99. 99.
    Scoll BJ, Wong YN, Egleston BL, Kunkle DA, Saad IR, Uzzo RG. Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol. 2009;181(2):506–11.PubMedCentralPubMedCrossRefGoogle Scholar
  100. 100.
    Sun M, Abdollah F, Bianchi M, et al. A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis. Eur Urol. 2011;60(6):1152–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Cloutier V, Capitanio U, Zini L, et al. Thirty-day mortality after nephrectomy: clinical implications for informed consent. Eur Urol. 2008;56(6):998–1003.PubMedCrossRefGoogle Scholar
  102. 102.
    Corman JM, Penson DF, Hur K, et al. Comparison of complications after radical and partial nephrectomy: results from the National Veterans Administration Surgical Quality Improvement Program. BJU Int. 2000;86(7):782–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Urologic Institute, University Hospitals Case Medical CenterClevelandUSA
  2. 2.Urology, Cleveland ClinicClevelandUSA

Personalised recommendations